CTSO — Cytosorbents Corporation

Summary of Cytosorbents Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Full Year 2025 Revenue: $37.1 million, up 4% year-over-year, with record core product sales.
• Q4 2025 Revenue: $9.2 million, a slight increase of 1% year-over-year but down 8% on a constant currency basis.
• Gross Margin: 71% for the full year, improving to 74% in Q4 due to manufacturing efficiencies.
• Operating Loss: Improved by 10% to $14.7 million for the year; Q4 operating loss was $4.6 million.
• Net Loss: Q4 net loss of $5.5 million ($0.09 per share), improved from $7.6 million ($0.14 per share) in Q4 2024.
• Adjusted EBITDA Loss: $10.5 million for the year, $3.2 million for Q4, worsening from $2.4 million in Q4 2024.
• Cash Position: $7.8 million at year-end, down from $9.1 million at the end of Q3 2025, with a net operating cash burn of $3.8 million in Q4.

2. Strategic Updates and Business Highlights

• Sales Growth: Strong international performance, with direct sales outside Germany up 13% and distributor sales up 11.4%, accounting for 68% of total revenue.
• PuriFi Initiative: Launched a stand-alone hemoperfusion pump to expand access to CytoSorb therapy, with over 100 units placed globally.
• DrugSorb-ATR Progress: Continued FDA discussions following a denied De Novo submission; a pre-submission meeting held in January 2026 to clarify requirements for a resubmission.
• Clinical Evidence: Increasing peer-reviewed publications and positive outcomes from studies supporting CytoSorb's efficacy in critical care.

3. Forward Guidance and Outlook

• 2026 Expectations: Aiming for cash flow breakeven in the second half of 2026, driven by cost reductions and improved operational efficiencies.
• Sales Strategy: Focus on consistent revenue growth, particularly in Germany, where early signs of improvement are noted.
• DrugSorb-ATR Resubmission: Aiming for a more streamlined submission process with better alignment with FDA expectations.

4. Bad News, Challenges, or Points of Concern

• Decline in Germany Sales: A 10% decrease in sales in Germany due to restructuring efforts, impacting overall revenue growth.
• Operating Expenses: Increased operating expenses in Q4 to $11.4 million, including a $500,000 restructuring charge.
• Cash Burn: Continued cash burn in Q4, exacerbated by increased inventory levels, although improvements in cash flow are expected as working capital normalizes.

5. Notable Q&A Insights

• FDA Submission Timeline: Management is cautious about the timing of the DrugSorb-ATR resubmission, prioritizing alignment with FDA to avoid another denial.
• German Market Improvement: Early signs of improvement in sales and engagement in Germany, attributed to leadership changes and a more structured sales approach.
• Gross Margin Projections: Management expects gross margins to remain in the low 70% range for the near term, with potential for improvement as volumes increase.
• PuriFi Revenue Model: The PuriFi pump is seen as a long-term investment with hopes for future revenue growth from disposables linked to its use.

This summary encapsulates the key points from the earnings call, highlighting both the positive developments and the challenges faced by Cytosorbents as they navigate their strategic initiatives and financial performance.